Press Release Description

Global Reproductive Genetics Market to Grow at a CAGR of 12% in the Forecast Period of 2021-26

The “Global Reproductive Genetics Market” is likely to grow at a CAGR of 12% in the forecast period of 2021-26, says MarkNtel Advisors in their research report. The market growth primarily attributes to the burgeoning awareness for such tests and increasing average age of women with first childbirth, especially in developed countries, including the U.S., England, France, Germany, Italy, and Japan, thereby leading to a surge in pregnancy complications.

According to OECD, between 1970-2017, most Organization for Economic Co-operation and Development (OECD) countries saw a mean age increase by somewhere between 2-5 years.

Moreover, the research report, “Global Reproductive Genetics Market Analysis, 2021,” cites that as the demand continues, reimbursement improves, and the technology expands to additional novel applications, the reproductive genetics market is poised to have substantial investment and growth.

Key Questions Answered in the Study

  1. What are the current and future trends in the Global Reproductive Genetics market?
  2. How has the industry been evolving in terms of geography and services adoption?
  3. How has the competition been shaping across the globe, followed by their comparative factorial indexing?
  4. What are the key growth drivers and challenges for the Global Reproductive Genetics market?
  5. What are the customer orientation, purchase behavior, and expectations from the Global Reproductive Genetics market service providers?

Next-Generation Sequencing Accounted for Significant Share of the Global Reproductive Genetics Market

The Global Reproductive Genetics Market includes four technologies, viz. Next-Generation Sequencing, Polymerase Chain Reaction, In-Situ Hybridization, and Microarray. Next-Generation Sequencing is the leading contributor to the Global Reproductive Genetics Market, accounted for around 30% of the market share in the previous year.

Sequencing methods have one of the most incredible impacts on healthcare services worldwide. With genomic information coming to the forefront of disease diagnosis, new disease genes identification and aberrations in non-coding regions in the whole genome have become easy. Additionally, with the rapid implementation of applications in emerging fields such as Pre-Natal screening, carrier screening, and other early-stage diagnoses, sequencing has significantly increased the number of approaches, which further helps in targeting various genetic abnormalities.

“Global Reproductive Genetics Market Analysis, 2021” provides comprehensive, qualitative, and quantitative insights on the market potential, key factors impacting the market growth, hotspots, and opportunities available for Reproductive Genetics providers across the globe. Moreover, the report also encompasses the key strategic imperatives for competitors' success and strategic factorial indexing to measure their capabilities on 16 parameters, which will help companies formulate 'Go to Market' strategies and identify the blue ocean for their offerings.

Europe to Witness Fastest Growth Rate During the Forecast Period

Europe is likely to witness the fastest growth in the Global Reproductive Genetics Market during the forecast period. The Reproductive Genetics Market in Europe has been growing since its inception. Several European countries, including France, Germany, the U.K., Spain, and Italy, are working persistently to enhance the adoption of such genetic testing for expecting parents and pregnant women across Europe.

However, there is a wide variation in the pre-implantation genetic diagnosis policies across Europe that often hampers the implantation and advancements of reproductive genetics in the region, reveals MarkNtel Advisors in their research report, “Global Reproductive Genetics Market Analysis, 2021.”

According to MarkNtel Advisors, the leading players in the Global Reproductive Genetics Market are ThermoFisher Scientific, Eurofins Scientific SE, Natera Inc., BGI Genomics, Illumina, Inc., Agilent Technologies, Inc., CENTOGENE AG, Fulgent Genetics, Inc., F. Hoffmann-La Roche Ltd, Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Quest Diagnostics, and QIAGEN NV.

Market Segmentation:

  1. By Procedure Type (Carrier Screening, Pre-Natal Screening, Pre-Implantation Genetic Testing, Infertility Genetic Testing)
  2. By Product Type (Kits, Laboratory Developed Tests, Reagents & Consumables)
  3. By Technology (Next Generation Sequencing, Polymerase Chain Reaction, In-Situ Hybridization, Microarray)
  4. By Application (Aneuploidy, Structural Chromosomal Abnormality, Single Gene Disorder, Others)
  5. By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa)
  6. By Country (U.S, Canada, Mexico, Brazil, Germany, France, The U.K, Spain, Italy, China, India, Japan, South Korea, Australia)
  7. By Competitors (ThermoFisher Scientific, Eurofins Scientific SE, Natera Inc., BGI Genomics, Illumina, Inc., Agilent Technologies, Inc., CENTOGENE AG, Fulgent Genetics, Inc., F. Hoffmann-La Roche Ltd, Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Quest Diagnostics, QIAGEN NV)